Hudson Bay Capital Management Portfolio holdings
AUM
$15.2B
1-Year Return
11.47%
This Quarter Return
+3.61%
1 Year Return
+11.47%
3 Year Return
+62.45%
5 Year Return
+105.91%
10 Year Return
+214.7%
AUM
$13.3B
AUM Growth
+$1.89B
(+17%)
Cap. Flow
-$206M
Cap. Flow
% of AUM
-1.54%
Top 10 Holdings %
Top 10 Hldgs %
40.07%
Holding
884
New
220
Increased
141
Reduced
144
Closed
206
Top Buys
| 1 |
Eli Lilly
LLY
|
+$353M |
| 2 |
Brookfield
BN
|
+$270M |
| 3 |
Dollar Tree
DLTR
|
+$267M |
| 4 |
Amazon
AMZN
|
+$241M |
| 5 |
TSMC
TSM
|
+$213M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$714M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$309M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$259M |
| 4 |
Tesla
TSLA
|
+$249M |
| 5 |
iShares MSCI ACWI ETF
ACWI
|
+$220M |
Sector Composition
| 1 | Technology | 29.66% |
| 2 | Consumer Discretionary | 12.97% |
| 3 | Healthcare | 10.88% |
| 4 | Financials | 8.34% |
| 5 | Industrials | 4.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
501
Amylyx Pharmaceuticals
AMLX
$937M
| $475K | ﹤0.01% |
250,000
-248,000
| -50% | -$471K |
|
502
Zegna
ZGN
$2.29B
| $474K | ﹤0.01% |
+40,000
| New | +$474K |
|
|
LGF.A
503
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
| $471K | ﹤0.01% |
+50,000
| New | +$471K |
|
|
RGLS
504
DELISTED
Regulus Therapeutics
RGLS
| $446K | ﹤0.01% |
249,940
-375,060
| -60% | -$669K |
|
505
NCR Atleos
NATL
$2.9B
| $437K | ﹤0.01% |
16,169
-15,092
| -48% | -$408K |
|
|
ONYX
506
DELISTED
Onyx Acquisition Co. I Class A Ordinary Shares
ONYX
| $430K | ﹤0.01% |
+37,925
| New | +$430K |
|
507
Origin Materials
ORGN
$78.5M
| $424K | ﹤0.01% |
470,685
-56,687
| -11% | -$51.1K |
|
508
Cellectar Biosciences
CLRB
$16.9M
| $375K | ﹤0.01% |
5,000
| – | – |
|
509
Travere Therapeutics
TVTX
$1.93B
| $366K | ﹤0.01% |
+44,561
| New | +$366K |
|
510
Coherent
COHR
$15.5B
| $362K | ﹤0.01% |
5,000
-10,000
| -67% | -$725K |
|
511
Recursion Pharmaceuticals
RXRX
$2.05B
| $338K | ﹤0.01% |
45,000
+15,000
| +50% | +$113K |
|
512
Philip Morris
PM
$256B
| $335K | ﹤0.01% |
+3,309
| New | +$335K |
|
513
NextCure
NXTC
$13.6M
| $324K | ﹤0.01% |
16,983
| – | – |
|
|
IGMS
514
DELISTED
IGM Biosciences
IGMS
| $317K | ﹤0.01% |
+46,119
| New | +$317K |
|
|
JWN
515
DELISTED
Nordstrom
JWN
| $295K | ﹤0.01% |
+13,884
| New | +$295K |
|
516
Silicon Motion
SIMO
$2.85B
| $277K | ﹤0.01% |
3,416
-57,746
| -94% | -$4.68M |
|
517
GrafTech
EAF
$220M
| $269K | ﹤0.01% |
+27,713
| New | +$269K |
|
518
Sony
SONY
$172B
| $264K | ﹤0.01% |
+15,550
| New | +$264K |
|
519
Elicio Therapeutics
ELTX
$190M
| $200K | ﹤0.01% |
+48,720
| New | +$200K |
|
|
LUNRW
520
DELISTED
Intuitive Machines, Inc. Warrants
LUNRW
| $198K | ﹤0.01% |
292,778
+42,778
| +17% | +$29K |
|
521
Sutro Biopharma
STRO
$82.3M
| $178K | ﹤0.01% |
+60,761
| New | +$178K |
|
522
Workhorse Group
WKHS
$18.3M
| $164K | ﹤0.01% |
8,448
| – | – |
|
523
Aptevo Therapeutics
APVO
$5.03M
| $153K | ﹤0.01% |
+676
| New | +$153K |
|
524
X4 Pharmaceuticals
XFOR
$73.6M
| $132K | ﹤0.01% |
+7,575
| New | +$132K |
|
525
Zura Bio
ZURA
$143M
| $122K | ﹤0.01% |
38,999
| – | – |
|